Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Rhea-AI Summary

Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The chat is scheduled for September 14 at 4:00 PM Eastern Time. Interested parties can access the presentation via a webcast on the company’s website. Immunovant is developing innovative therapies, including the investigational compound batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24^th Annual Global Investment Conference, taking place September 12^th-14^th, 2022.

H.C. Wainwright Global Investment Conference fireside chat details:

Date:	Thursday, September 14th, 2022
Time:	4:00 pm Eastern Time
Webcast:	The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com. 

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com

FAQ

When will Immunovant's CEO participate in the H.C. Wainwright Global Investment Conference?

Pete Salzmann, CEO of Immunovant, will participate in the fireside chat on September 14, 2022, at 4:00 PM Eastern Time.

How can I access the webcast for Immunovant's presentation?

The presentation can be accessed via webcast on Immunovant's Investor Relations section of their website at www.immunovant.com.

What is Immunovant's focus in the pharmaceutical industry?

Immunovant is focused on developing therapies for autoimmune diseases, utilizing their proprietary FcRn inhibitor technology.

What is batoclimab and its significance?

Batoclimab is Immunovant's investigational fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn), aimed at treating autoimmune diseases.

What are the dates for the H.C. Wainwright Global Investment Conference?

The H.C. Wainwright Global Investment Conference will be held from September 12 to September 14, 2022.